High-dose vitamin C for advanced plasma cell disorders
Part of Cancer clinical trials.
This trial tests whether high doses of vitamin C, given with standard chemotherapy, can help people with multiple myeloma or related plasma cell disorders who have already tried several treatments. It includes a stem cell transplant step, so you must have stored stem cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have myeloma or a similar plasma cell disorder and have tried 3 or more treatments (like proteasome inhibitors, lenalidomide, or daratumumab) that stopped working within the last 6 months.
- You are 18 years or older.
- You have stored at least 1 million CD34 stem cells per kilogram of your weight.
- Your disease is measurable by blood or urine tests (for example, M-protein in blood or urine, or high free light chains).
- Your heart, lungs, kidneys, and liver are working well enough (your doctor will check this with tests).
- You have an ECOG performance status of 0-2 (able to care for yourself and do light activities), or a higher status only due to bone pain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether HDP-101 is safe and can potentially help adults with multiple myeloma that has come back or didn’t respond to standard treatments. It focuses on people who have already tried key myeloma medicines and still have measurable disease.
This trial tests a special high-dose vitamin C infusion, given based on how your body processes it, for people with advanced solid tumors. It aims to see if this vitamin C therapy can be safely combined with your current or new chemotherapy to help control the cancer.
This trial tests if adding high-dose vitamin C (ascorbate) to a standard combination of azacitidine and venetoclax can help adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy. It aims to see if this combination is safe and effective.
This Phase 2 trial tests whether intravenous vitamin C (ascorbic acid) added to chemotherapy can improve outcomes for people with certain relapsed or treatment-resistant lymphomas or chronic myelomonocytic leukemia (CMML). It may help by boosting chemotherapy’s effectiveness and/or changing how the cancer responds.
This trial tests whether adding high-dose vitamin C (ascorbate) to a standard chemotherapy drug (azacitidine) helps people with higher-risk myelodysplastic syndrome (MDS). It is for those who have had little or no prior treatment for MDS.
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
Hear when a new Plasma Cell Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.